Michael Henderson
Chief Executive Officer bij APOGEE THERAPEUTICS, INC.
Vermogen: 41 M $ op 31-03-2024
Profiel
Michael Henderson richtte PellePharm, Inc. op. Hij is Chief Executive Officer voor QED Therapeutics, Inc., Chief Executive Officer bij Origin Biosciences, Inc. en Chief Business Officer voor BridgeBio Pharma, Inc. en zit in de raad van bestuur van 5 andere bedrijven. In het verleden bekleedde hij de functie van Senior Associate bij McKinsey & Co, Inc. Dr. Henderson behaalde een doctoraat aan de Harvard University en een doctoraat aan de Stanford University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
01-03-2024 | 609 740 ( 1.39% ) | 41 M $ | 31-03-2024 | |
31-01-2024 | 30 000 ( 0.80% ) | 336 900 $ | 31-03-2024 |
Actieve functies van Michael Henderson
Bedrijven | Functie | Begin |
---|---|---|
ARYA SCIENCES ACQUISITION CORP IV | Director/Board Member | 25-02-2021 |
SPYRE THERAPEUTICS, INC. | Director/Board Member | 22-06-2023 |
APOGEE THERAPEUTICS, INC. | Chief Executive Officer | 01-06-2023 |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Chief Executive Officer | - |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The private company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Chief Executive Officer | - |
Therasis, Inc.
Therasis, Inc. Pharmaceuticals: MajorHealth Technology Therasis, Inc. develops oncology drugs. It offers oncology therapeutics for use as single agents or in combination therapy. The firm's proprietary technology, the Therasis Filter, represents a paradigm shift in the ability to discover therapeutic targets, their chemical inhibitors, and associated biomarkers and this platform integrates world-class expertise in high throughput screening, systems biology, cancer genetics and clinical research. The company was founded by Owen A. O'Connor and Riccardo Dalla-Favera in 2007 and is headquartered in New York, NY. | Director/Board Member | 01-09-2016 |
Adrenas Therapeutics, Inc. | Director/Board Member | 01-07-2017 |
Quartz Therapeutics, Inc. | Director/Board Member | 01-09-2016 |
TheRas, Inc.
TheRas, Inc. Medical/Nursing ServicesHealth Services TheRas, Inc. engages in biotechnological research, which develops program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company is headquartered in Palo Alto, CA. | Director/Board Member | 01-09-2016 |
Eerdere bekende functies van Michael Henderson
Bedrijven | Functie | Einde |
---|---|---|
░░░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Opleiding van Michael Henderson
Harvard University | Undergraduate Degree |
Stanford University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
SPYRE THERAPEUTICS, INC. | Health Technology |
BRIDGEBIO PHARMA, INC. | Health Technology |
ARYA SCIENCES ACQUISITION CORP IV | Finance |
APOGEE THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 8 |
---|---|
PellePharm, Inc.
PellePharm, Inc. BiotechnologyHealth Technology PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA. | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Therasis, Inc.
Therasis, Inc. Pharmaceuticals: MajorHealth Technology Therasis, Inc. develops oncology drugs. It offers oncology therapeutics for use as single agents or in combination therapy. The firm's proprietary technology, the Therasis Filter, represents a paradigm shift in the ability to discover therapeutic targets, their chemical inhibitors, and associated biomarkers and this platform integrates world-class expertise in high throughput screening, systems biology, cancer genetics and clinical research. The company was founded by Owen A. O'Connor and Riccardo Dalla-Favera in 2007 and is headquartered in New York, NY. | Health Technology |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The private company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Health Technology |
Quartz Therapeutics, Inc. | |
Adrenas Therapeutics, Inc. | |
TheRas, Inc.
TheRas, Inc. Medical/Nursing ServicesHealth Services TheRas, Inc. engages in biotechnological research, which develops program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company is headquartered in Palo Alto, CA. | Health Services |